source
- FDA rejects Summit’s ivonescimab, citing China‑centric data and missed survival benefitThe FDA sent Summit Therapeutics a complete response letter on Nov 13, rejecting its PD‑1×VEGF bispecific antibody ivonescimab. Reviewers said the pivotal HARMONi trial was dominated by patients f…
- AI drugmaker Isomorphic Labs raises $5 billion in Series C roundIsomorphic Labs, an Alphabet spinout that applies artificial intelligence to drug discovery, announced a $5 billion Series C financing. The round was led by Greenoaks and Sequoia Capital, with Alp…